Literature DB >> 33881630

Integrating Measures of Myocardial Fibrosis in the Transition from Hypertensive Heart Disease to Heart Failure.

R Brandon Stacey1, W Gregory Hundley2,3.   

Abstract

PURPOSE OF REVIEW: This review aims to summarize recent developments in identifying and quantifying both the presence and amount of myocardial fibrosis by imaging and biomarkers. Further, this review seeks to describe in general ways how this information may be used to identify hypertension and the transition to heart failure with preserved ejection fraction. RECENT
FINDINGS: Recent studies using cardiac magnetic resonance imaging highlight the progressive nature of fibrosis from normal individuals to those with hypertension to those with clinical heart failure. However, separating hypertensive patients from those with heart failure remains challenging. Recent studies involving echocardiography show the subclinical myocardial strain changes between hypertensive heart disease and heart failure. Lastly, recent studies highlight the potential use of biomarkers to identify those with hypertension at the greatest risk of developing heart failure. In light of the heterogeneous nature between hypertension and heart failure with preserved ejection fraction, an integrated approach with cardiac imaging and biomarker analysis may enable clinicians and investigators to more accurately characterize, prevent, and treat heart failure in those with hypertension.

Entities:  

Keywords:  Heart failure with preserved ejection fraction; Hypertension; Left ventricular hypertrophy; Myocardial fibrosis

Year:  2021        PMID: 33881630     DOI: 10.1007/s11906-021-01135-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

Review 1.  The Transition From Hypertension to Heart Failure: Contemporary Update.

Authors:  Franz H Messerli; Stefano F Rimoldi; Sripal Bangalore
Journal:  JACC Heart Fail       Date:  2017-07-12       Impact factor: 12.035

Review 2.  The progression of hypertensive heart disease.

Authors:  Mark H Drazner
Journal:  Circulation       Date:  2011-01-25       Impact factor: 29.690

3.  Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani
Journal:  Circulation       Date:  2019-03-05       Impact factor: 29.690

4.  Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study.

Authors:  Franz Duca; Andreas A Kammerlander; Caroline Zotter-Tufaro; Stefan Aschauer; Marianne L Schwaiger; Beatrice A Marzluf; Diana Bonderman; Julia Mascherbauer
Journal:  Circ Cardiovasc Imaging       Date:  2016-12       Impact factor: 7.792

5.  Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018.

Authors:  Paul Muntner; Shakia T Hardy; Lawrence J Fine; Byron C Jaeger; Gregory Wozniak; Emily B Levitan; Lisandro D Colantonio
Journal:  JAMA       Date:  2020-09-22       Impact factor: 56.272

6.  Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.

Authors:  Andrew S Flett; Martin P Hayward; Michael T Ashworth; Michael S Hansen; Andrew M Taylor; Perry M Elliott; Christopher McGregor; James C Moon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 7.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance.

Authors:  Nathan Mewton; Chia Ying Liu; Pierre Croisille; David Bluemke; João A C Lima
Journal:  J Am Coll Cardiol       Date:  2011-02-22       Impact factor: 24.094

8.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

9.  T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.

Authors:  Rocio Hinojar; Niharika Varma; Nick Child; Benjamin Goodman; Andrew Jabbour; Chung-Yao Yu; Rolf Gebker; Adelina Doltra; Sebastian Kelle; Sitara Khan; Toby Rogers; Eduardo Arroyo Ucar; Ciara Cummins; Gerald Carr-White; Eike Nagel; Valentina O Puntmann
Journal:  Circ Cardiovasc Imaging       Date:  2015-12       Impact factor: 7.792

10.  Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes.

Authors:  Eric Y Yang; Mohammad A Khan; Edward A Graviss; Duc T Nguyen; Arvind Bhimaraj; Vijay Nambi; Ron C Hoogeveen; Christie M Ballantyne; William A Zoghbi; Dipan J Shah
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

View more
  2 in total

Review 1.  Sex, gender, and subclinical hypertensiveorgan damage-heart.

Authors:  Cesare Cuspidi; Elisa Gherbesi; Carla Sala; Marijana Tadic
Journal:  J Hum Hypertens       Date:  2022-08-27       Impact factor: 2.877

2.  microRNA-135a-5p regulates NOD-like receptor family pyrin domain containing 3 inflammasome-mediated hypertensive cardiac inflammation and fibrosis via thioredoxin-interacting protein.

Authors:  Hao Chen; Huilian Qiao; Qiang Zhao; Fuling Wei
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.